Clinical and economic outcomes for patients initiating fluticasone propionate/salmeterol combination therapy (250/50 mcg) versus anticholinergics in a comorbid COPD/depression population

Dalal AA, Shah M, D'Souza AO, Chaudhari S, Crater G

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
22315518

DOI
10.2147/COPD.S27846

Original Paper URL
http://www.dovepress.com/clinical-and-economic-outcomes-for-patients-initiating-fluticasone-pro-peer-reviewed-article-COPD

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Albuterol /analogs & derivatives /therapeutic use; Androstadienes /therapeutic use; Cholinergic Antagonists /therapeutic use; Cost of Illness; Depression /drug therapy /economics /epidemiology; Drug Combinations; Female; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Follow-Up Studies; Glucocorticoids /therapeutic use; Hospitalization /economics; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive /drug therapy /economics /epidemiology; Retrospective Studies; Treatment Outcome

AccessionNumber
22012010268

Date bibliographic record published
13/02/2013